MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andriy Turhovach who wrote (1110)	9/15/1998 12:07:00 PM
From: Russian Bear	Read Replies (1) of 1826

Everyone, I spoke with Lori Weiman of IR, earlier today. She was somewhat limited in what she could say, especially now that the quarter is drawing to a close. A quick synopsis: INFeD sales are not expected to be effected by the Schein/Steris problems. There is product in the channel, and production at Steris is likely to resume shortly, in any event. She would not comment on Salagen sales. She only said that the sales and marketing folks did not yet have prescription refill data, as of the last time she enquired, about 10 days ago. I am looking forward very much to this information, when it becomes available. Lori confirmed that the Phase I MGI-114 trial is still ongoing, and will remain so for the foreseeable future. Now that they have established the MTD, they are adding more and more patients at that dose in an effort to gather more information. This is standard practice. She added that, in addition to the ongoing prostate PII trial, MGI will be launching two other PII trials (one for ovarian and another for pancreatic cancer) by the end of 1998. FWIW, RB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next